Brilinta reduces risk of cardiovascular events in patients with coronary artery disease and Type 2 diabetes

Brilinta reduces risk of cardiovascular events in patients with coronary artery disease and Type 2 diabetes

AstraZeneca has announced detailed results positive Brilinta reduces risk Phase III trial, heart attack, a significant reduction. The overall trial population was patients coronary artery disease (CAD) type 2 diabetes (T2D) no prior heart attack stroke. Additionally, a procedure open a blocked coronary artery, heart attack, aspirin alone. The profile for BRILINTA was known profile medicine an risk bleeding events in both THEMIS-PCI sub-analysis.

Cardiac disease is a group of disorders of blood vessels and heart. Congenital heart defects, coronary artery disease and heart rhythm problems are some of the major cardiac diseases. Most common cause of heart disease is narrowing or blockage of blood vessels and coronary artery i. e. ischemic heart disease. Cardiac disease is mainly caused due to high cholesterol, smoking and high blood pressure. In addition, several other diseases such as, diabetes and obesity, and lifestyle changes such as poor coronary blockage nutrition, excessive alcohol and physical inactivity causes higher risk of cardiac diseases. In the U. S. heart disease is the leading cause of death in men and women. According to Centers for Disease Control and Prevention in 2010, in the U. S. approximately 600,000 people die due to heart disease. Prevention or control of heart disease is essential. Prevention from heart disease can be done by, controlling high blood pressure, lifestyle changes, lowering cholesterol, exercising and maintaining health weight.

Myocardial or heart attack an irreversible acute medical which caused due blockage one coronary blockage developed due buildup atherosclerotic on walls In most cases, anterior, lateral or walls left heart. which leads myocardial in humans. Some medications usually used for treatment myocardial as follows: Antiplatelet Trends in the Vorapaxar Clopidogrel Glycoprotein IIb/IIIa Abciximab Tirofiban Eptifibatide Antithrombotic Heparin Bivalirudin Enoxaparin Beta-adrenergic Metoprolol Esmolol Vasodilators Nitroglycerin Enzyme (ACE) Enalapril Lisinopril Angiotensin-Receptor Candesartan Cardiac Bio-Implant Devices Analgesics Morphine sulfate Thrombolytics Alteplase (t-PA) Browse More Detail About This Report At.

Comments

Popular posts from this blog

NutraVesta ProVen Reviews - Groundbreaking New Report For ProVen Weight Loss

MD Anderson Remains Top-Ranked Cancer Center

The Missing Link for Cardiovascular Disease in Type 1 Diabetes Mellitus? Hyperglycemia-induced Cardiac Autoimmunity